Programs

MC-30

Head and Neck cancer is the 6th most common form of cancer worldwide. For many patients, survival is measured in months, not years.MC-30 aims to give years of quality life back to many patients by correcting the underlying mutation that creates resistance to treatment

MC-DX4

FSHD is one of the most common muscular dystrophies, with over 40,000 patients in the US. There are no FDA approved treatments for this disease. MC-DX4 aims to stop disease progression in patients by eliminating expression of the toxic DUX4 protein in muscle tissue.